December 13, 2007 – A Canadian nuclear reactor that makes and distributes globally more than two-thirds of the world’s supply of radioisotopes for cancer tests, may reopen by Dec. 20, after being shut down since November.

Atomic Energy of Canada Ltd. (ACEL), a government-owned nuclear technology company that operates the reactor, shut it down after technical problems. Pending a push through emergency legislation allowing AECL to use a backup method, the reactor should be back to full production within seven days.

The Ontario Association of Nuclear Medicine says about 50,000 Canadians and 160,000 Americans would have their tests postponed for each month the reactor remains shut down.

The company says it could restart the reactor now using an emergency pump but the Canadian Nuclear Safety Commission does not agree. The government is trying to aim legislation to temporarily sideline the watchdog and allow the reactor to operate for 120 days.

For more information: www.aecl.ca


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now